ImmuCell Q1 product sales up 11% to $8.1M, net income $1.4M ($0.16 EPS) vs loss year ago

IMMUCELL CORP /DE/

2025-Q1 EPS reported $0.16 revenue$8,067,174

Q1 product sales $8.1M (record high), up 11% YoY; 6-month sales $15.8M (+28%).
Net income $1.4M ($0.16 diluted EPS) vs net loss of $438K ($0.06 loss) in Q1 2024.
Gross margin improved to 42% from 32% YoY; adjusted EBITDA $2.3M for Q1.
Cash $4.6M, no draw on $1M line; working capital $12.1M, equity $29M.
Contract manufacturer issues delay Re-Tain; company exploring strategic options for the technology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.